MetaCap

Sanofi (SNY) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vertex Pharmaceuticals (VRTX) has outperformed Sanofi (SNY) over the past year, gaining 20.7% versus a loss of 6.3%. Over five years, VRTX leads with a +180.5% price change compared with -3.7% for SNY. Vertex Pharmaceuticals is the larger company by market cap ($130.58 billion vs $111.70 billion), about 1.2 times the size.

On valuation, Sanofi trades at a lower forward P/E (8.6x vs 25.9x for Vertex Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SNY-6.27%VRTX+20.68%
+34%+5%-24%
Nov 21, 20251 yearNov 20, 2026
SNY-8.12%VRTX+181.62%
+217%+90%-36%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SNY versus VRTX key metrics
MetricSNYVRTX
Share price$46.52$515.02
Market cap$111.70B$130.58B
1-day change+1.00%-1.08%
YTD return-4.00%+13.60%
1-year return-6.27%+20.68%
5-year return-3.69%+180.53%
P/E ratio (TTM)23.1433.14
Forward P/E8.5725.86
EPS (TTM)$2.01$15.54
Dividend yield5.20%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$12.00B
Revenue growth (YoY)—+8.90%
Net income (latest FY)—$3.95B
Gross margin—86.24%
Operating margin—34.77%
Net margin—32.94%
52-week high$50.61$568.67
52-week low$39.07$412.27
Distance from 52-week high-8.08%-9.43%
Analyst consensusbuybuy
Avg. price target upside+18.06%+15.60%
Average volume3.41M1.25M
Shares outstanding2.40B253.54M
Employees74,8466,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRTX has outperformed SNY by 26.9 percentage points over the past year.
  • Vertex Pharmaceuticals trades at a higher earnings multiple (33.1x vs 23.1x trailing P/E).
  • Sanofi offers a meaningfully higher dividend yield (5.20% vs 0.00%).

About Sanofi

SNY stock →

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.

Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

SNY vs VRTX FAQ

Which is bigger, Sanofi or Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $130.58B compared with $111.70B for Sanofi (SNY).

Which stock has performed better over the past year, SNY or VRTX?

VRTX returned +20.68% over the past 12 months, compared with -6.27% for SNY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, SNY or VRTX?

SNY has the lower trailing P/E at 23.1, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Sanofi or Vertex Pharmaceuticals?

Sanofi pays a dividend yielding 5.20%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Sanofi and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons